Treatment of impulse control disorders in Parkinson’s disease: Practical considerations and future directions

References

• Voon V, Fox SH. Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch Neurol. 2007;64(8):1089–1096.
   PubMedGoogle Scholar
• Giovannoni G, O’Sullivan JD, Turner K, et al. Hedonistic homeostatic dysregulation in patients with Parkinson’s disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry. 2000;68(4):423–428.
   PubMed Web of Science ®Google Scholar
• Lim SY, Evans AH, Miyasaki JM. Impulse control and related disorders in Parkinson’s disease: review. Ann N Y Acad Sci. 2008;1142:85–107.
   PubMed Web of Science ®Google Scholar
• Phu AL, Xu Z, Brakoulias V, et al. Effect of impulse control disorders on disability and quality of life in Parkinson’s disease patients. J Clin Neurosci. 2014;21(1):63–66.
   PubMed Web of Science ®Google Scholar
• Leroi I, Harbishettar V, Andrews M, et al. Carer burden in apathy and impulse control disorders in Parkinson’s disease. Int J Geriatr Psychiatry. 2012;27(2):160–166.
   PubMed Web of Science ®Google Scholar
• Baumann-Vogel H, Valko PO, Eisele G, et al. Impulse control disorders in Parkinson’s disease: don’t set your mind at rest by self-assessments. Eur J Neurol. 2015;22:603–609.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Siderowf AD, Potenza MN, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol. 2006;63(7):969–973.
   PubMedGoogle Scholar
• Voon V, Sohr M, Lang AE, et al. Impulse control disorders in Parkinson disease: a multicenter case–control study. Ann Neurol. 2011;69(6):986–996.
   PubMed Web of Science ®Google Scholar
• Lee JY, Kim JM, Kim JW, et al. Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease. Parkinsonism Relat Disord. 2010;16(3):202–207.
   PubMed Web of Science ®Google Scholar
• Delaney M, Leroi I, Simpson J, et al. Impulse control disorders in Parkinson’s disease: a psychosocial perspective. J Clin Psychol Med Settings. 2012;19(3):338–346.
   PubMed Web of Science ®Google Scholar
• Perez-Lloret S, Rey MV, Fabre N, et al. Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease. Clin Neuropharmacol. 2012;35(6):261–265.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Sohr M, Potenza MN, et al. Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol. 2010;68(6):963–968.
   PubMed Web of Science ®Google Scholar
• Voon V, Thomsen T, Miyasaki JM, et al. Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol. 2007;64(2):212–216.
   PubMedGoogle Scholar
• Wu K, Politis M, O’Sullivan SS, et al. Single versus multiple impulse control disorders in Parkinson’s disease: an (11)C-raclopride positron emission tomography study of reward cue-evoked striatal dopamine release. J Neurol. 2015;262(6):1504–1514.
   PubMed Web of Science ®Google Scholar
• Potenza MN, Voon V, Weintraub D. Drug Insight: impulse control disorders and dopamine therapies in Parkinson’s disease. Nat Clin Pract Neurol. 2007;3(12):664–672.
   PubMedGoogle Scholar
• Gallagher DA, O’Sullivan SS, Evans AH, et al. Pathological gambling in Parkinson’s disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. Move Disord: Off J Move Disord Soc. 2007;22(12):1757–1763.
   PubMed Web of Science ®Google Scholar
• Weintraub D. Dopamine and impulse control disorders in Parkinson’s disease. Ann Neurol. 2008;64(Suppl 2):S93–100.
   Google Scholar
• Giugni JC, Tschopp L, Escalante V, et al. Dose-dependent impulse control disorders in piribedil overdose. Clin Neuropharmacol. 2012;35(1):49–50.
   PubMed Web of Science ®Google Scholar
• Tschopp L, Salazar Z, Gomez Botello MT, et al. Impulse control disorder and piribedil: report of 5 cases. Clin Neuropharmacol. 2010;33(1):11–13.
   PubMed Web of Science ®Google Scholar
• Micheli FE, Giugni JC, Espinosa ME, et al. Piribedil and pathological gambling in six parkinsonian patients. Arq Neuropsiquiatr. 2015;73(2):115–118.
   PubMed Web of Science ®Google Scholar
• Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson’s disease. Pathophysiologic and clinical implications. N Engl J Med. 1988;318(14):876–880.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67(5):589–595.
   PubMed Web of Science ®Google Scholar
• Napier TC, Corvol JC, Grace AA, et al. Linking neuroscience with modern concepts of impulse control disorders in Parkinson’s disease. Move Disord: Off J Move Disord Soc. 2015;30(2):141–149.
   PubMed Web of Science ®Google Scholar
• Carriere N, Lopes R, Defebvre L, et al. Impaired corticostriatal connectivity in impulse control disorders in Parkinson disease. Neurology. 2015;84(21):2116–2123.
   PubMed Web of Science ®Google Scholar
• Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol. 2010;67(1):58–63.
   PubMedGoogle Scholar
• Mamikonyan E, Siderowf AD, Duda JE, et al. Long-term follow-up of impulse control disorders in Parkinson’s disease. Mov Disord. 2008;23(1):75–80.
   PubMed Web of Science ®Google Scholar
• Sohtaoglu M, Demiray DY, Kenangil G, et al. Long term follow-up of Parkinson’s disease patients with impulse control disorders. Parkinsonism Relat Disord. 2010;16(5):334–337.
   PubMed Web of Science ®Google Scholar
• Mestre TA, Strafella AP, Thomsen T, et al. Diagnosis and treatment of impulse control disorders in patients with movement disorders. Ther Adv Neurol Disord. 2013;6(3):175–188.
   PubMed Web of Science ®Google Scholar
• Okai D, Samuel M, Askey-Jones S, et al. Impulse control disorders and dopamine dysregulation in Parkinson’s disease: a broader conceptual framework. Eur J Neurol. 2011;18(12):1379–1383.
   PubMed Web of Science ®Google Scholar
• Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A, et al. Impulse control disorder in patients with Parkinson’s disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry. 2014;85(8):840–844.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Hsu A, Kell S, et al. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson’s disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol. 2013;12(4):346–356.
   PubMed Web of Science ®Google Scholar
• Evans AH, Pavese N, Lawrence AD, et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol. 2006;59(5):852–858.
   PubMed Web of Science ®Google Scholar
• Catalan MJ, De Pablo-Fernandez E, Villanueva C, et al. Levodopa infusion improves impulsivity and dopamine dysregulation syndrome in Parkinson’s disease. Move Disord: Off J Move Disord Soc. 2013;28(14):2007–2010.
   PubMed Web of Science ®Google Scholar
• Todorova A, Samuel M, Brown RG, et al. Infusion therapies and development of impulse control disorders in advanced Parkinson disease: clinical experience after 3 years’ follow-up. Clin Neuropharmacol. 2015;38(4):132–134.
   PubMed Web of Science ®Google Scholar
• Cilia R, Siri C, Canesi M, et al. Dopamine dysregulation syndrome in Parkinson’s disease: from clinical and neuropsychological characterisation to management and long-term outcome. J Neurol Neurosurg Psychiatry. 2014;85(3):311–318.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141–149.
   PubMed Web of Science ®Google Scholar
• Cannas A, Solla P, Marrosu MG, et al. Dopamine dysregulation syndrome in Parkinson’s disease patients on duodenal levodopa infusion. Move Disord: Off J Move Disord Soc. 2013;28(6):840–841.
   PubMed Web of Science ®Google Scholar
• Chang FC-F, K V, Van der Poorten D, et al. Levodopa-carbidopa intestinal gel infusion improves motor performance and quality of life in patients with advanced Parkinson’s disease. J Clin Neurosci. 2014;21(11):2033.
   Google Scholar
• Rizos A-M-MP, Martin A, European multicentre survey of tolerability rates and impulse control behaviour trends of prolonged release dopamine agonists in young and old PD. Move Disord: Off J Move Disord Soc. 2012;27(Suppl 1):S:50.
   Google Scholar
• Schreglmann SR, Gantenbein AR, Eisele G, et al. Transdermal rotigotine causes impulse control disorders in patients with restless legs syndrome. Parkinsonism Relat Disord. 2012;18(2):207–209.
   PubMed Web of Science ®Google Scholar
• Samuel M, Rodriguez-Oroz M, Antonini A, et al. Management of impulse control disorders in Parkinson’s disease: Controversies and future approaches. Move Disord: Off J Move Disord Soc. 2015;30(2):150–159.
   PubMed Web of Science ®Google Scholar
• Garcia Ruiz PJ, Sesar Ignacio A, Ares Pensado B, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease with motor fluctuations: a multicenter study. Move Disord: Off J Move Disord Soc. 2008;23(8):1130–1136.
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Reddy P, Katzenschlager R, et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson’s disease. Move Disord: Off J Move Disord Soc. 2015;30(4):510–516.
   PubMed Web of Science ®Google Scholar
• Thomas A, Bonanni L, Gambi F, et al. Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol. 2010;68(3):400–404.
   PubMed Web of Science ®Google Scholar
• Walsh RA, Lang AE. Multiple impulse control disorders developing in Parkinson’s disease after initiation of amantadine. Mov Disord. 2012;27(2):326.
   PubMedGoogle Scholar
• Fasano A, Ricciardi L, Pettorruso M, et al. Management of punding in Parkinson’s disease: an open-label prospective study. J Neurol. 2011;258(4):656–660.
   PubMed Web of Science ®Google Scholar
• Kashihara K, Imamura T. Amantadine may reverse punding in Parkinson’s disease–observation in a patient. Mov Disord. 2008;23(1):129–130.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Nelson EB, Welge JA, et al. Olanzapine in the treatment of pathological gambling: a negative randomized placebo-controlled trial. J Clin Psychiatry. 2008;69(3):433–440.
   PubMed Web of Science ®Google Scholar
• Smith N, Kitchenham N, Bowden-Jones H. Pathological gambling and the treatment of psychosis with aripiprazole: case reports. Br J Psychiatry: J Ment Sci. 2011;199(2):158–159.
   PubMed Web of Science ®Google Scholar
• Miwa H, Morita S, Nakanishi I, et al. Stereotyped behaviors or punding after quetiapine administration in Parkinson’s disease. Parkinsonism Relat Disord. 2004;10(3):177–180.
   PubMed Web of Science ®Google Scholar
• Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. Jama. 2014;311(16):1670–1683.
   PubMed Web of Science ®Google Scholar
• Hardwick A, Ward H, Hassan A, et al. Clozapine as a potential treatment for refractory impulsive, compulsive, and punding behaviors in Parkinson’s disease. Neurocase. 2013;19(6):587–591.
   PubMed Web of Science ®Google Scholar
• Bonfils NA, Benyamina A, Aubin HJ, et al. Clozapine use for refractory impulse control disorders in Parkinson’s disease: a case report. Psychopharmacology (Berl). 2015;232(19):3677–3679.
   PubMed Web of Science ®Google Scholar
• Sriram A, Ward HE, Hassan A, et al. Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson’s disease. J Neurol. 2013;260(2):521–527.
   PubMed Web of Science ®Google Scholar
• Hicks CW, Pandya MM, Itin I, et al. Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson’s disease. Parkinsonism Relat Disord. 2011;17(5):379–381.
   PubMed Web of Science ®Google Scholar
• Epstein J, Madiedo CJ, Lai L, et al. Successful treatment of dopamine dysregulation syndrome with valproic acid. J Neuropsychiatry Clin Neurosci. 2014;26(3):E3.
   Google Scholar
• Bermejo PE. Topiramate in managing impulse control disorders in Parkinson’s disease. Parkinsonism Relat Disord. 2008;14(5):448–449.
   PubMed Web of Science ®Google Scholar
• Bermejo PE, Ruiz-Huete C, Anciones B. Zonisamide in managing impulse control disorders in Parkinson’s disease. J Neurol. 2010;257(10):1682–1685.
   PubMed Web of Science ®Google Scholar
• Bosco D, Plastino M, Colica C, et al. Opioid antagonist naltrexone for the treatment of pathological gambling in Parkinson disease. Clin Neuropharmacol. 2012;35(3):118–120.
   PubMed Web of Science ®Google Scholar
• Bortolato M, Cannas A, Solla P, et al. Finasteride attenuates pathological gambling in patients with Parkinson disease. J Clin Psychopharmacol. 2012;32(3):424–425.
   PubMed Web of Science ®Google Scholar
• Okai D, Askey-Jones S, Samuel M, et al. Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. Neurology. 2013;80(9):792–799.
   PubMed Web of Science ®Google Scholar
• Isaias IU, Siri C, Cilia R, et al. The relationship between impulsivity and impulse control disorders in Parkinson’s disease. Move Disord: Off J Move Disord Soc. 2008;23(3):411–415.
   PubMed Web of Science ®Google Scholar
• Moum SJ, Price CC, Limotai N, et al. Effects of STN and GPi deep brain stimulation on impulse control disorders and dopamine dysregulation syndrome. PLoS One. 2012;7(1):e29768.
   PubMed Web of Science ®Google Scholar
• Lhommee E, Klinger H, Thobois S, et al. Subthalamic stimulation in Parkinson’s disease: restoring the balance of motivated behaviours. Brain. 2012;135(Pt 5):1463–1477.
   PubMed Web of Science ®Google Scholar
• Shotbolt P, Moriarty J, Costello A, et al. Relationships between deep brain stimulation and impulse control disorders in Parkinson’s disease, with a literature review. Parkinsonism Relat Disord. 2012;18(1):10–16.
   PubMed Web of Science ®Google Scholar
• Amami P, Dekker I, Piacentini S, et al. Impulse control behaviours in patients with Parkinson’s disease after subthalamic deep brain stimulation: de novo cases and 3-year follow-up. J Neurol Neurosurg Psychiatry. 2015;86(5):562–564.
   PubMed Web of Science ®Google Scholar
• Gee L, Smith H, De La Cruz P, et al The influence of bilateral subthalamic nucleus deep brain stimulation on impulsivity and prepulse inhibition in Parkinson’s disease patients. Stereotact Funct Neurosurg. 2015;93(4):265–270.
   PubMed Web of Science ®Google Scholar
• Ardouin C, Voon V, Worbe Y, et al. Pathological gambling in Parkinson’s disease improves on chronic subthalamic nucleus stimulation. Mov Disord. 2006;21(11):1941–1946.
   PubMed Web of Science ®Google Scholar
• Bandini F, Primavera A, Pizzorno M, et al. Using STN DBS and medication reduction as a strategy to treat pathological gambling in Parkinson’s disease. Parkinsonism Relat Disord. 2007;13(6):369–371.
   PubMed Web of Science ®Google Scholar
• Witjas T, Baunez C, Henry JM, et al. Addiction in Parkinson’s disease: impact of subthalamic nucleus deep brain stimulation. Mov Disord. 2005;20(8):1052–1055.
   PubMed Web of Science ®Google Scholar
• Knobel D, Aybek S, Pollo C, et al. Rapid resolution of dopamine dysregulation syndrome (DDS) after subthalamic DBS for Parkinson disease (PD): a case report. Cogn Behav Neurol: Off J Soc Behav Cogn Neurol. 2008;21(3):187–189.
   PubMed Web of Science ®Google Scholar
• Halbig TD, Tse W, Frisina PG, et al. Subthalamic deep brain stimulation and impulse control in Parkinson’s disease. Eur J Neurol. 2009;16(4):493–497.
   PubMed Web of Science ®Google Scholar
• Murata M, Hasegawa K, Kanazawa I, et al. Zonisamide improves wearing-off in Parkinson’s disease: A randomized, double-blind study. Move Disord: Off J Move Disord Soc. 2015;30(10):1343–1350.
   PubMed Web of Science ®Google Scholar
• Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord. 2011;26(Suppl 3):S42–80.
   PubMed Web of Science ®Google Scholar
• Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry. 2005;162(8):1403–1413.
   PubMed Web of Science ®Google Scholar
• Hamilton J, Lee J, Canales JJ. Chronic unilateral stimulation of the nucleus accumbens at high or low frequencies attenuates relapse to cocaine seeking in an animal model. Brain Stimul. 2015;8(1):57–63.
   PubMed Web of Science ®Google Scholar